Home » Clinical Trials » Therapeutic Areas
Therapeutic Areas: Oncology | Obstetrics/Gynecology (Women’s Health) | Family Medicine
Disease Category: Breast Cancer
Location: United States, IL
NSABP B-47 Phase III Randomized Study of Adjuvant Chemotherapy With Versus Without Trastuzumab in Women With Node-Positive or High-Risk Node-Negative HER2-Low Invasive Breast Cancer
To determine whether the addition of trastuzumab to chemotherapy (TC or AC→WP) improves invasive disease-free survival (IDFS) in women with resected node-positive or high-risk node-negative breast cancer which is reported as HER2-low by all HER2 testing performed.
Patient Inclusion Criteria:
Patient Exclusion Criteria:
CW ID: 183096
Date Last Changed:
November 6, 2014
Janeen V. Bazan, RN OCN BSN CCRP, Oncology Research Nurse Program CoordinatorAdvocate Sherman Hospital1425 North Randall RoadElgin, IL 60123Phone: 224-783-2907Fax: 224-783-3071
Research Center Information: Advocate Sherman Hospital
If you would like to learn more about participating in this research study, please email the trial contact using the form below.
DISCLAIMER: CenterWatch does not conduct clinical research.
CenterWatch is a publishing company that posts clinical trials information on behalf of sponsor companies,
contract research organizations, clinical research sites and other interested parties. This information
is designed to help patients find clinical trials of interest and contact the research centers
conducting the trials.
Copyright © 1995-2015 CenterWatch.